AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20456697 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal strategy with RBC storage time > 14 days
Number of subjects: 455
Study 20456697 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive strategy with RBC storage time > 21 days
Number of subjects: 455
Study 20456697 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined groups with RBC storage time > 14 days
Number of subjects: 455
Study 20456697 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined groups with RBC storage time > 21 days
Number of subjects: 455
Study 18729687 — intervention group
Group type: EXPERIMENTAL
Intervention: Single context extinction (extinction to alcohol cues in the same context for 3 sessions followed by a context shift at the fourth session)
Number of subjects: 73
Study 18729687 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple context extinction (extinction to alcohol cues in different contexts each day for all 4 sessions)
Number of subjects: 73
Study 18729687 — intervention group
Group type: COMPARATOR
Intervention: Pseudoextinction control condition (exposure to neutral cues in the same context for 3 sessions followed by exposure to alcohol cues at the fourth session)
Number of subjects: 73
Study 12775025 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized chemotherapy based on gene expression profiles
Number of subjects: 30
Study 12775025 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment without gene expression profiles)
Number of subjects: 30
Study 11778496 — intervention group
Group type: EXPERIMENTAL
Intervention: M. vaccae + chemotherapy
Number of subjects: 90
Study 11778496 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only (Control)
Number of subjects: 90
Study 11778496 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by M. vaccae (Self control)
Number of subjects: 90
Study 9316525 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin (150 IU/kg body weight every 12 h during the hospital period)
Number of subjects: 776
Study 9316525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 776
Study 9316525 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 776
Study 8165385 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbidopa/levodopa (25/100 mg and 50/200 mg)
Number of subjects: 6
Study 8165385 — intervention group
Group type: EXPERIMENTAL
Intervention: Propoxyphene (100 mg and 200 mg)
Number of subjects: 6
Study 8165385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2427838 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol 200 mg once daily for one week, followed by 400 mg once daily for the third week
Number of subjects: 23
Study 2427838 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (exact dosage not specified during crossover phase)
Number of subjects: 23
Study 2427838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 29520465 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular dysfunction (RV ejection fraction < 44% or RV fractional area of change < 35%)
Number of subjects: 365
Study 29520465 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of Blalock-Taussig (BT) shunt, large RV, post-Norwood infectious complication, and surgeon performing five or less Norwood procedures per year
Number of subjects: 365
Study 29520465 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with all four identified risk factors
Number of subjects: 365
Study 27977774 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 237
Study 27977774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study 24788217 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated data analysis with individualized written advice on appropriate health services (Intervention Group)
Number of subjects: 514
Study 24788217 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control Group)
Number of subjects: 514
Study 22726105 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin α-1 plus peginterferon α-2a (180 μg weekly for 48 weeks and 1.6 mg twice a week for the first 12 weeks)
Number of subjects: 51
Study 22726105 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon α-2a monotherapy (180 μg weekly for 48 weeks)
Number of subjects: 51
Study 19747581 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg oSCT
Number of subjects: 73
Study 19747581 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg oSCT
Number of subjects: 73
Study 19747581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 18165796 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg
Number of subjects: 27
Study 18165796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 16129366 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy followed by surgery (80 mg/m² cisplatin on day 1, 800 mg/m² fluorouracil on days 1-4, with concurrent radiotherapy of 35 Gy in 15 fractions)
Number of subjects: 256
Study 16129366 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy followed by surgery
Number of subjects: 256
Study 16129366 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 256
Study 12538460 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 90 mg/m(2) followed by paclitaxel 250 mg/m(2) (or reverse)
Number of subjects: 29
Study 12538460 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 60 mg/m(2) and paclitaxel 175 mg/m(2)
Number of subjects: 29
Study 10024611 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior protein intake of 0.8 g protein. kg‐1. d‐1
Number of subjects: 3
Study 10024611 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior protein intake of 1.4 g protein. kg‐1. d‐1
Number of subjects: 3
Study 10024611 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior protein intake of 2.0 g protein. kg‐1. d‐1
Number of subjects: 3
Study 10024611 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid‐based formula diet containing 1 g protein. kg‐1. d‐1
Number of subjects: 3
Study 8711700 — intervention group
Group type: EXPERIMENTAL
Intervention: Open acromioplasty
Number of subjects: 0
Study 8711700 — intervention group
Group type: COMPARATOR
Intervention: Closed percutaneous acromioplasty
Number of subjects: 0
Study 1844994 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% glucose polymer beverage containing electrolytes (GP)
Number of subjects: 44
Study 1844994 — intervention group
Group type: COMPARATOR
Intervention: Nonnutrient, nonelectrolyte placebo (P)
Number of subjects: 44
Study 6417996 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent nasogastric feeding (2-h bolus administration)
Number of subjects: 10
Study 6417996 — intervention group
Group type: COMPARATOR
Intervention: Continuous nasogastric feeding (24 h/day)
Number of subjects: 10
Study 31005176 — intervention group
Group type: EXPERIMENTAL
Intervention: 3T MRI
Number of subjects: 982
Study 31005176 — intervention group
Group type: COMPARATOR
Intervention: 1.5T MRI
Number of subjects: 982
Study 28939746 — intervention group
Group type: EXPERIMENTAL
Intervention: Radotinib 300 mg
Number of subjects: 241
Study 28939746 — intervention group
Group type: EXPERIMENTAL
Intervention: Radotinib 400 mg
Number of subjects: 241
Study 28939746 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 400 mg
Number of subjects: 241
Study 26511965 — intervention group
Group type: EXPERIMENTAL
Intervention: Waves aquatic exercise classes (n = 67)
Number of subjects: 109
Study 26511965 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 42)
Number of subjects: 109
Study 25081721 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous tumor lysate primed mature DC (arm III)
Number of subjects: 14
Study 25081721 — intervention group
Group type: EXPERIMENTAL
Intervention: Unprimed mature DC (arm II)
Number of subjects: 14
Study 25081721 — intervention group
Group type: COMPARATOR
Intervention: Saline control (arm I)
Number of subjects: 14
Study 21523892 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary bolus-only tirofiban (n = 25)
Number of subjects: 49
Study 21523892 — intervention group
Group type: COMPARATOR
Intervention: Intravenous bolus plus infusion of tirofiban (n = 24)
Number of subjects: 49
Study 18975259 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy weight strength training (HWT)
Number of subjects: 16
Study 18975259 — intervention group
Group type: COMPARATOR
Intervention: Explosive strength training (EST)
Number of subjects: 16
Study 17341128 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR), 25% caloric restriction
Number of subjects: 36
Study 17341128 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction with exercise (CREX), 12.5% caloric restriction + 12.5% increased energy expenditure
Number of subjects: 36
Study 17341128 — intervention group
Group type: COMPARATOR
Intervention: Control, 100% of energy requirements
Number of subjects: 36
Study 15285862 — intervention group
Group type: EXPERIMENTAL
Intervention: Single high dose steroid treatment in addition to intravenous antibiotic therapy
Number of subjects: 62
Study 15285862 — intervention group
Group type: COMPARATOR
Intervention: Intravenous antibiotic therapy with a single dose placebo
Number of subjects: 62
Study 11352443 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400mg alone
Number of subjects: 12
Study 11352443 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400mg with ferrous sulfate (Eryfer 100 equivalent to 100mg of Fe2+)
Number of subjects: 12
Study 9207997 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus johnsonii La1
Number of subjects: 12
Study 9207997 — intervention group
Group type: COMPARATOR
Intervention: Control (fermented milk without La1)
Number of subjects: 12
Study 8355154 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 0.03%
Number of subjects: 233
Study 8355154 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 233
Study 3316309 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide 5 mg
Number of subjects: 1185
Study 3316309 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide 10 mg
Number of subjects: 1185
Study 3316309 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplementation (16.8 or 33.6 mmol potassium chloride)
Number of subjects: 1185
Study 3316309 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg + Amiloride 2.5 mg
Number of subjects: 1185
Study 3316309 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 50 mg + Amiloride 5 mg
Number of subjects: 1185
Study 29175360 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 300
Study 29175360 — intervention group
Group type: COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 300
Study 29175360 — intervention group
Group type: COMPARATOR
Intervention: Auricular point pressing
Number of subjects: 300
Study 27692704 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 31
Study 27692704 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 31
Study 27692704 — intervention group
Group type: COMPARATOR
Intervention: Both anesthetics
Number of subjects: 31
Study 25164306 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-degree laterally wedged insole
Number of subjects: 12
Study 25164306 — intervention group
Group type: COMPARATOR
Intervention: Neutral insole
Number of subjects: 12
Study 22387529 — intervention group
Group type: EXPERIMENTAL
Intervention: telaprevir plus peginterferon/ribavirin
Number of subjects: 161
Study 21055212 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical expansive open door laminoplasty (EOLP) with hinge at the inner margin of the lateral mass (wide-open group)
Number of subjects: 102
Study 21055212 — intervention group
Group type: COMPARATOR
Intervention: Cervical expansive open door laminoplasty (EOLP) with hinge at the lamina margin (narrow-open group)
Number of subjects: 102
Study 18407793 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ(10) 100 mg, riboflavin 10 mg and niacin 50 mg (CoRN) along with tamoxifen (TAM) 10 mg twice a day for 45 days (Group IV)
Number of subjects: 84
Study 18407793 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ(10) 100 mg, riboflavin 10 mg and niacin 50 mg (CoRN) along with tamoxifen (TAM) 10 mg twice a day for 90 days (Group V)
Number of subjects: 84
Study 18407793 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM) 10 mg twice a day
Number of subjects: 84
Study 16422829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional interferon alpha-2b (5 x 10(6) units)
Number of subjects: 39
Study 16422829 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 mL saline)
Number of subjects: 39
Study 12760524 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar occupations rated by children
Number of subjects: 92
Study 12760524 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel occupations depicted with African Americans
Number of subjects: 92
Study 12760524 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's age and socioeconomic background
Number of subjects: 92
Study 12950423 — intervention group
Group type: EXPERIMENTAL
Intervention: Asimadoline 0.5 mg
Number of subjects: 39
Study 12950423 — intervention group
Group type: EXPERIMENTAL
Intervention: Asimadoline 1.5 mg
Number of subjects: 39
Study 12950423 — intervention group
Group type: EXPERIMENTAL
Intervention: Asimadoline
Number of subjects: 39
Study 12950423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 9877445 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaseron (interferon-beta1b)
Number of subjects: 0
Study 8556078 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicle stimulating hormone (FSH)
Number of subjects: 232
Study 8556078 — intervention group
Group type: COMPARATOR
Intervention: Human menopausal gonadotropin (HMG)
Number of subjects: 232
Study 2374772 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright white light exposure for 7 days from 7.20 to 9.20 a.m.
Number of subjects: 30
Study 2374772 — intervention group
Group type: COMPARATOR
Intervention: Dim light exposure
Number of subjects: 30
Study 369263 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine: 1 gr./day
Number of subjects: 36
Study 369263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 369263 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 36
Study 30604111 — intervention group
Group type: EXPERIMENTAL
Intervention: e-book
Number of subjects: 30
Study 30604111 — intervention group
Group type: COMPARATOR
Intervention: printed book
Number of subjects: 30
Study 28252600 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromidin (ipidacrine)
Number of subjects: 64
Study 28252600 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 64
Study 25686801 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational family intervention
Number of subjects: 326
Study 25686801 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 326
Study 25686801 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 326
Study 23585286 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride 100 mg dose
Number of subjects: 16
Study 21757655 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline concentrations of circulating interleukin-10 (IL-10)
Number of subjects: 2437
Study 19467958 — intervention group
Group type: EXPERIMENTAL
Intervention: ICEC‐R (randomised clinical trials comprehension inventory)
Number of subjects: 474
Study 19467958 — intervention group
Group type: EXPERIMENTAL
Intervention: STAI‐Y (trait-state anxiety scale)
Number of subjects: 474
Study 19467958 — intervention group
Group type: EXPERIMENTAL
Intervention: SAT (satisfaction about care scale)
Number of subjects: 474
Study 16737398 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety information
Number of subjects: 31
Study 16737398 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety information plus safety cue
Number of subjects: 31
Study 16737398 — intervention group
Group type: COMPARATOR
Intervention: No safety information
Number of subjects: 31
Study 15574110 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper Limb Group
Number of subjects: 30
Study 15574110 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobility Group
Number of subjects: 30
Study 11205487 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group status (not specified in detail)
Number of subjects: 4477
Study 11205487 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline perceived risk
Number of subjects: 4477
Study 11205487 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking status (for men without polyps)
Number of subjects: 4477
Study 11205487 — intervention group
Group type: EXPERIMENTAL
Intervention: Year 2 perceived risk
Number of subjects: 4477
Study 11205487 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief in salience and coherence of screening (for men with polyps)
Number of subjects: 4477
Study 11205487 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to be screened (for men with polyps)
Number of subjects: 4477
Study 11205487 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to screening at the worksite (for men with polyps)
Number of subjects: 4477
Study 11205487 — intervention group
Group type: EXPERIMENTAL
Intervention: Specificity and sensitivity of models
Number of subjects: 4477
Study 9421324 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin for 10 days prior to surgery
Number of subjects: 60
Study 9421324 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil for 10 days prior to surgery
Number of subjects: 60
Study 9421324 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 60
Study 8305993 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-masked design
Number of subjects: 102
Study 8305993 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of all randomized patients
Number of subjects: 102
Study 8305993 — intervention group
Group type: EXPERIMENTAL
Intervention: Methodologic quality
Number of subjects: 102
Study 3500684 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 62
Study 3500684 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 62
Study 3500684 — intervention group
Group type: COMPARATOR
Intervention: Antacids
Number of subjects: 62
Study 29943744 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Vitamin D supplementation
Number of subjects: 948
Study 29943744 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral Vitamin D supplementation
Number of subjects: 948
Study 28541588 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity walking protocol
Number of subjects: 78
Study 28541588 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 78
Study 25308883 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage (MLD) sessions (10 sessions over 4 weeks)
Number of subjects: 41
Study 23515684 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin
Number of subjects: 70
Study 23515684 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 70
Study 21617262 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomile solution (twice-a-day application)
Number of subjects: 72
Study 21617262 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone 1% ointment (once-a-day application)
Number of subjects: 72
Study 19725827 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 0
Study 19725827 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 0
Study 16894619 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER (75 mg/day or 150 mg/day)
Number of subjects: 664
Study 16894619 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (40 mg/day)
Number of subjects: 664
Study 16894619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 664
Study 16894619 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (Venlafaxine ER or Paroxetine)
Number of subjects: 664
Study 15215096 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg per day
Number of subjects: 154
Study 15215096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 11800414 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril plus canreonate (25 mg/day)
Number of subjects: 187
Study 11800414 — intervention group
Group type: COMPARATOR
Intervention: Captopril alone (placebo)
Number of subjects: 187
Study 9726220 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodiabsorption device (BioLogic‐DT System)
Number of subjects: 11
Study 9726220 — intervention group
Group type: COMPARATOR
Intervention: Standard intensive care procedures
Number of subjects: 11
Study 7976145 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia initiated 30 min before surgical incision
Number of subjects: 32
Study 7976145 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia initiated at closure of the surgical wound
Number of subjects: 32
Study 2658637 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin treatment (100, 150, or 200 micrograms/kg at 1 or 2 year intervals)
Number of subjects: 39
Study 1092973 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylpropion hydrochloride (Tenuate Dospan)
Number of subjects: 102
Study 1092973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 1092973 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylpropion hydrochloride (Tenuate Dospan) after crossover to placebo
Number of subjects: 102
Study 1092973 — intervention group
Group type: COMPARATOR
Intervention: Placebo after crossover to diethylpropion hydrochloride
Number of subjects: 102
Study 29641242 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture intervention (weekly or biweekly individualized treatments)
Number of subjects: 104
Study 28967801 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin
Number of subjects: 14
Study 26141682 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-supported cognitive behavioral therapy
Number of subjects: 160
Study 26141682 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light
Number of subjects: 160